Table 3.
Randomized clinical trials with eltrombopag in cirrhosis
| Author / study | Patients | Control | New therapy | Na | Response rateb | No platelet transfusionc |
|---|---|---|---|---|---|---|
| McHutchison, 2007 [57] | cirrhosis, hepatitis C | placebo | Elt 50d | 37 | 0 vs. 79e p < 0.001 | |
| McHutchison, 2007 [57] | cirrhosis, hepatitis C | placebo | Elt 754 | 41 | 0 vs. 95e p < 0.001 | |
| Afdhal, 2013 [56] | cirrhosis, elective surgery platelets <50,000/μl | placebo | Elt 75 | 292 | 19 vs. 72 p < 0.001 |
a
Number of patients
b
% of patients with platelets ≥100,000/µl at the end of initial treatment phase.
c
% of patients with ≥50,000/µl for at least 6 weeks.
d
Number indicates the dose in mg.
e
Results for controls vs. results for new therapy.